Background prior art Analysis of the pipeline databases to date indicate that there are several adrenergic ?? 2 -antagonists in the market, by companies including Akzo Nobel (Organon), Novartis, Pfizer, and Schering AG. None of those compounds are selective for any of the three ?? 2 -adrenoceptors.